HCW Biologics (HCWB) Projected to Post Quarterly Earnings on Friday

HCW Biologics (NASDAQ:HCWB) is expected to be issuing its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of ($1.98) per share and revenue of $5.7270 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of ($2.64) by $3.01. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The firm had revenue of $6.54 million for the quarter, compared to the consensus estimate of $6.54 million.

HCW Biologics Price Performance

HCWB opened at $3.60 on Wednesday. HCW Biologics has a fifty-two week low of $1.50 and a fifty-two week high of $44.10. The business has a 50-day moving average of $5.97 and a 200-day moving average of $5.14. The company has a market capitalization of $5.76 million, a PE ratio of -0.06 and a beta of 2.32.

Insider Buying and Selling at HCW Biologics

In other HCW Biologics news, Director Scott T. Garrett bought 29,656 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was purchased at an average price of $8.46 per share, for a total transaction of $250,889.76. Following the purchase, the director directly owned 33,906 shares in the company, valued at $286,844.76. This trade represents a 697.79% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders bought 47,500 shares of company stock worth $310,875. 9.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned approximately 9.15% of HCW Biologics as of its most recent SEC filing. 2.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on HCWB. Wall Street Zen upgraded HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. Maxim Group increased their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.